Olympus Partners announced it has acquired PAI Pharma, a leading developer, manufacturer, and distributor of generic oral liquids in both ready-to-dose cups and bottles in the US.
PAI provides the broadest portfolio of generic oral liquid medicines in the industry, meeting the unique needs of retail chains, independent pharmacies, hospitals, long-term care facilities, and government agencies. The company is based in Parsippan,y, N.J. and operates from two large manufacturing campuses in Greenville, S.C.
The Olympus team included Griffin Barstis, Jim Conroy, George Swenson, Rabela Bodini, and Lester Coleman. And Olympus was represented by Matt Goulding and Matt Dunnet from Kirkland & Ellis.
KEY QUOTES:
“PAI has been at the forefront of manufacturing better-targeted suspensions, oral solutions, and liquids across a variety of packaging formats for nearly 50 years. We are excited to work with a team that has a track record as impressive as PAI as they continue their mission of delivering medications safely, reliably, and affordably.”
– Griffin Barstis, partner at Olympus
“The team and I are thrilled to partner with Olympus as we continue our evolution as a company. Given their experience and success, we are certain they will be invaluable partners as we look to accelerate our growth.”
– Kurt Orlofski, CEO of PAI
